What Is the Growth Potential of the Rare Disease Genetic Testing Market in the Next Decade?
The rare disease genetic testing market size has grown rapidly in recent years. It will grow from $1.03 billion in 2024 to $1.17 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing awareness about rare genetic disorders, rising demand for early and accurate diagnosis, rise in government funding for rare disease research, increasing availability of genetic testing services, increasing precision medicine investments, and increasing incidence of rare genetic conditions.
The rare disease genetic testing market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing adoption of next-generation sequencing, rising focus on personalized medicine, growing investments in genetic research, expanding healthcare infrastructure in emerging markets, a rise in diagnostic testing, increase in hereditary cancer testing, and rising demand for non-invasive diagnostic solutions. Major trends in the forecast period include advancement in genome editing technologies, advanced bioinformatics tools for genetic data analysis, innovation in multi-gene panel testing, advancement in portable genetic testing devices, and innovation in sample collection techniques.
Claim your free report sample now:
What Are the Critical Growth Contributors in the Rare Disease Genetic Testing Market?
The increasing genetic disorders are expected to propel the growth of the rare disease genetic testing market going forward. Genetic disorders refer to medical conditions caused by abnormalities in an individual's deoxyribonucleic acid, inherited from one or both parents or arising from new mutations. The increasing genetic disorders are increasing due to rising parental age, as older parents have a higher risk of passing on genetic mutations to their children. Rare disease genetic testing helps in the diagnosis of genetic disorders by identifying specific mutations, enabling accurate and early detection. It supports personalized treatment planning, enhancing patient care and improving long-term health outcomes. For instance, in May 2024, according to the National Health Service, a UK-based government department, there are 17,000 people living with sickle cell disease, an inherited genetic blood disorder, with around 250 new cases diagnosed each year. Therefore, the increasing genetic disorders are driving the growth of the rare disease genetic testing market.
Which Segments Are Attracting Maximum Investment in the Rare Disease Genetic Testing Market?
The rare disease genetic testing market covered in this report is segmented
1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types
2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies
3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests
4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders
2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension
3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders
4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions
5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders
6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders
7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions
What Are the Key Trends Shaping the Rare Disease Genetic Testing Market?
Major companies operating in the rare disease genetic testing market are focusing on developing technologically advanced solutions, such as digital genomics platforms, to enhance the speed, accuracy, and scalability of rare disease diagnosis. Digital genomics platforms are advanced software systems that integrate genomic data analysis, interpretation, and reporting to streamline and accelerate genetic testing and diagnosis. For instance, in March 2025, Strand Life Sciences Private Limited, an India-based computer software company, launched StrandOmics Portal, a digital platform aimed at enhancing the efficiency and accuracy of rare disease diagnosis. The portal offers clinicians in-depth insights into genetic variants, enabling quicker and more precise diagnoses. It supports advanced variant interpretation, including prenatal diagnostics, and facilitates independent reviews of genetic data. This launch underscores a strong commitment to advancing precision medicine and providing healthcare professionals with effective tools to enhance patient outcomes.
Which Are the Major Market Players in the Rare Disease Genetic Testing Industry?
Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Realm IDX Inc., Artemis DNA Inc., BGI Genomics Co. Ltd.
Get the full rare disease genetic testing market report here:
Which Regions Are Forecasted to Experience the Fastest Growth in the Rare Disease Genetic Testing Market?
North America was the largest region in the rare disease genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment